SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-21-026016
Filing Date
2021-02-22
Accepted
2021-02-22 08:55:08
Documents
5
Period of Report
2021-03-24

Document Format Files

Seq Description Document Type Size
1 DEF 14A tm215484-2_def14a.htm DEF 14A 522507
2 GRAPHIC lg_outlook-therapeutics.jpg GRAPHIC 41051
3 GRAPHIC tm215484d1-pc_1page.jpg GRAPHIC 587754
4 GRAPHIC tm215484d1-pc_2page.jpg GRAPHIC 424170
5 GRAPHIC tm215484d1-pc_3page.jpg GRAPHIC 744337
  Complete submission text file 0001104659-21-026016.txt   2997074
Mailing Address 4260 U.S. ROUTE 1 MONMOUTH JUNCTION NJ 08852
Business Address 4260 U.S. ROUTE 1 MONMOUTH JUNCTION NJ 08852 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

IRS No.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: DEF 14A | Act: 34 | File No.: 001-37759 | Film No.: 21658390
SIC: 2836 Biological Products, (No Diagnostic Substances)